Axsome Therapeutics

Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axsome Therapeutics reports robust Q4 performance and eyes global expansion

Axsome Therapeutics had a strong Q4 2022, driven by successful commercialization of Auvelity and Sunosi.
While facing challenges such as legal disputes and payer coverage, the company is well-positioned for growth.
Strategic opportunities in expanding product portfolio and market access present avenues for future success.
Financially stable with a focus on innovation, Axsome is poised for continued growth and market expansion.

Axsome Therapeutics excels in Q1 2023 despite financial hurdles

Axsome Therapeutics demonstrated strong commercial and pipeline progress in Q1 2023, despite financial challenges.
The company's focus on expanding market share and optimizing commercial operations bodes well for future growth.
While facing challenges in sales guidance and NDA filings, Axsome's strong financial position and product performance offer opportunities for sustained success.

Axsome Therapeutics reports robust Q2 sales and expands product portfolio

Axsome Therapeutics demonstrated strong sales performance driven by Auvelity and Sunosi, with a focus on future growth potential.
Despite challenges such as increased costs and a net loss, the company is strategically expanding its product portfolio and market reach.
Opportunities lie in new FDA indications for existing products and the goal to have five marketed products by 2025.

Axsome Therapeutics reports robust Q3 earnings and outlines growth strategies

Axsome Therapeutics delivered strong revenue growth in Q3 2023, driven by Auvelity and Sunosi, showcasing a promising commercial outlook.
The company's pipeline progress and upcoming milestones reflect a commitment to innovation and expansion in the CNS therapeutic space.
While challenges like ongoing losses and strategic resource allocation persist, opportunities in new markets and product diversification offer avenues for future growth.

Axsome Therapeutics reports robust 2023 performance and eyes growth opportunities

Axsome Therapeutics had a strong financial performance in 2023, driven by the success of Auvelity and Sunosi. Despite challenges like increased expenses and net loss, opportunities for growth exist through new indications and expanded payer coverage.

Axsome Therapeutics excels in Q1 2024, poised for growth

Axsome Therapeutics demonstrated exceptional financial growth and pipeline advancements in Q1 2024, particularly in neuroscience programs like AXS-12.
Strong commercial performance of Auvelity and Sunosi, coupled with stable payer coverage and growth strategies, underpin the company's success trajectory.
While facing challenges related to study timelines and cybersecurity, Axsome Therapeutics remains poised to capitalize on upcoming milestones and market opportunities.

Axsome Therapeutics excels in Q2 2024, eyes market expansion

Axsome Therapeutics delivered a strong performance in Q2 2024, driven by revenue growth and progress on key product developments.
While facing challenges in market competition and operational execution, the company remains optimistic about future prospects.
Strategic opportunities in market expansion and product innovation position Axsome well for sustained growth and success in the CNS treatment space.

Axsome Therapeutics excels in Q3 with record revenue and pipeline progress

Axsome Therapeutics delivered a strong performance in Q3 2024, surpassing $100 million in quarterly product revenue and maintaining a solid financial position.
The company's strengths lie in its successful products, robust pipeline, and strategic commercial initiatives, supported by a strong cash reserve.
Challenges include managing expenses, navigating market dynamics, and sustaining commercial momentum, while opportunities exist in product launches and market expansion.
Overall, Axsome's performance reflects a balanced approach to growth, innovation, and market competitiveness, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome (AXSM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axsome (AXSM) Upgraded to Strong Buy: Here's What You Should Know

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

NEW YORK, July 07, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of solriamfetol, an investigational treatment for attention deficit hyperactivity disorder (ADHD) in adults.

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

MercadoLibre

NextEra Energy

PayPal

Starbucks

MercadoLibre and Axsome Therapeutics are two exciting growth stocks that are worth a look. NextEra Energy and Starbucks can afford to continue raising their dividends year after year.

5 Top Stocks for July

NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the closing of its previously announced underwritten public offering of 3,000,000 shares of its common stock at the public offering price of $75.00 per share. The aggregate gross proceeds to Axsome, before deducting underwriting discounts and commissions and offering expenses, were $225.0 million.

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Axsome (AXSM) Down on Public Offering of Common Stock

The company wanted to raise money while the stock's price was relatively high. Axsome saw increased revenue and earnings in the first quarter.

Why Shares of Axsome Therapeutics Fell Wednesday

Axsome Therapeutics (NASDAQ: AXSM ) stock is heading lower on Wednesday as investors react to the company pricing a public share offering. Axsome Therapeutics is selling 3 million shares of AXSM stock at a price of $75 each.

Why Is Axsome Therapeutics (AXSM) Stock Down 10% Today?

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $75.00 per share. The proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Axsome, are expected to be $225.0 million. In addition, Axsome has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 30, 2023, subject to customary closing conditions.

Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock

CRISPR Therapeutics

Axsome Therapeutics' exciting pipeline promises a bright future for the company. CRISPR Therapeutics is on the verge of what could be the first of many approvals.

2 Under-the-Radar Biotech Stocks to Buy in 2023

NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. In addition, Axsome intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions. All of the shares in the offering are to be sold by Axsome.

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

Cue Biopharma

Viking Therapeutics

With patent expirations around the corner, some of the biggest pharmaceutical and biotech companies will soon face generic competition, creating a big opportunity for these top biotech stocks to buy. In 2023 alone, pharmaceutical and biotech companies spent about $85 billion on acquisitions.

3 Biotech Stocks to Buy as Companies Ink Major Deals

Axsome's two new products are seeing prescription growth. The company aims to launch four more products in just a couple of years.

Where Will Axsome Therapeutics Be in 3 Years?

Axsome Therapeutics made waves recently by suggesting that the drugs in its catalog and pipeline could reach total peak annual U.S. sales of $11.5 billion. Axsome Therapeutics' market value at the moment has only factored in a fraction of the company's potential peak sales estimate.

Does an $11.5 Billion Opportunity Make This Growth Stock a Buy Now?

Axsome Therapeutics shares soared more than 100% last year after its first two products launched. It may have more on the way.

This Stock Crushed the Market Last Year. Here's Why It Could Do That Again.

Yesterday, Axsome Therapeutics provided an overview on the commercial prospects of its robust CNS pipeline. The biotech has the pieces in place to create tremendous organically driven growth in the years ahead.

Is Axsome Therapeutics Stock a Screaming Buy?

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?

Axsome Therapeutics, Inc. NDA resubmission of AXS-07 for treatment of patients with migraine expected 2nd half 2023 after FDA meeting determined that CMC issues are the only things that need to be addressed. It is expected that the global migraine drugs market will reach $10.86 billion by 2030. NDA submission of AXS-14 for the treatment of patients with fibromyalgia expected Q4 of 2023.

Axsome: NDA Resubmission AXS-07 And Other Catalysts Make This A Must Watch

Axsome expects its eight products to generate up to $11.5 billion in peak U.S. sales. AXSM stock zoomed higher Wednesday.

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?

Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?

Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea Cognitive improvement with Sunosi sustained over eight hours in patients with excessive daytime sleepiness due to obstructive sleep apnea

Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with obstructive sleep apnea NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations on Auvelity® (dextromethorphan-bupropion), Sunosi® (solriamfetol), and disease state at the upcoming American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, being held from May 30-June 3 in Miami. The presentations on Auvelity incorporate new data and post-hoc analyses including demonstration of functional improvement in patients with major depressive disorder (MDD).

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

CRISPR Therapeutics is awaiting approval for a potential multi-billion product. Axsome Therapeutics has several clinical and regulatory milestones ahead.

Prediction: These 2 Stocks Could Double In the Next Year

Vertex Pharmaceuticals

Axsome has two approved treatments as well as candidates in late-stage development Vertex has the dominant treatment for cystic fibrosis and is developing other products.

2 Biotech Stocks That Could Help Set You Up for Life

Sanofi

Sanofi's wide lineup of medicines across several therapeutic areas makes it attractive. Axsome Therapeutics is rising in prominence thanks to an exciting pipeline.

News for Axsome Therapeutics Stock (AXSM)